In patients with diabetes, the randomized intention-to-treat analysis estimated a lower 3.5-year primary composite cardiovascular outcome risk with liraglutide than placebo (11.8% versus 13.3%; risk difference 1.5%, 95% CI 0.1-2.9).
In plain wordsIn people with diabetes, liraglutide had a lower estimated three-and-a-half-year risk of the primary cardiovascular outcome than placebo.
- Peptide
- Liraglutide
- Outcome
- DecreasePrimary composite cardiovascular outcome, intention-to-treat analysis
- Study
n: not reported in source
- Comparator
- Placebo
- Analysis
- Primary
- Outcome group
- Cardiovascular events · Cardiovascular
- Studied dose
- Dose not stated
Measurements
- 3.5-year risk
- 11.8%
- liraglutide; 95% CI 10.8-12.8
- 3.5-year risk
- 13.3%
- placebo; 95% CI 12.3-14.3
- Risk difference
- 1.5%
- 95% CI 0.1-2.9
Source sentences
The intention-to-treat analysis estimated 3.5-year risks for the primary composite outcome of 11.8% (95% confidence interval: 10.8 to 12.8) in the liraglutide arm and 13.3% (95% confidence interval: 12.3 to 14.3) in the placebo arm, with a risk difference of 1.5% (95% confidence interval: 0.1 to 2.9).
3 context sentences(design, population, supporting numbers)
The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results trial randomized patients with diabetes to liraglutide or placebo.
The results were compared to the intention-to-treat analysis.
We report 3.5-year risks of the primary composite outcome (myocardial infarction, stroke, or cardiovascular mortality) and secondary outcomes (each of the primary outcome's components, revascularization, unstable angina pectoris, heart failure, and all-cause mortality).